{
    "nct_id": "NCT05675449",
    "official_title": "A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA",
    "inclusion_criteria": "* Prior diagnosis of multiple myeloma as defined by IMWG criteria.\n* Measurable disease based on IMWG criteria as defined by at least 1 of the following:\n\n  * Serum M-protein ≥0.5 g/dL.\n  * Urinary M-protein excretion ≥200 mg/24 hours.\n  * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).\n* Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).\n* Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody.\n* ECOG performance status 0-1.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.\n* Not pregnant or breastfeeding and willing to use contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM\n* Impaired cardiovascular function or clinically significant cardiovascular diseases.\n* Participants with any active, uncontrolled bacterial, fungal, or viral infection.\n* Stem cell transplant within 12 weeks prior to enrollment, or active graft versus host disease.\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n* Part 1: Previous treatment with a BCMA-directed therapy.\n* Part 2: Previous treatment with any anti-BCMA directed therapy, with the exception of CAR-T. Previous treatment with a CD47-SIRP alpha-directed therapy.\n* Part 1: Prior treatment with carfilzomib\n* Live attenuated vaccine within 4 weeks of the first dose of study intervention.\n* Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.\n* Any of the following within 3 months of enrollment: erosive esophagitis, treatment resistant peptic ulcer, infectious or inflammatory bowel disease, pulmonary embolism or uncontrolled thromboembolic event.\n* Intolerance to or participants who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or therapeutic proteins",
    "miscellaneous_criteria": ""
}